The University of Southampton
University of Southampton Institutional Repository

Which factors predict placebo response in anxiety disorders and major depression? An analysis of placebo-controlled studies of escitalopram

Which factors predict placebo response in anxiety disorders and major depression? An analysis of placebo-controlled studies of escitalopram
Which factors predict placebo response in anxiety disorders and major depression? An analysis of placebo-controlled studies of escitalopram
Background: The placebo response rate has increased in several psychiatric disorders and is a major issue in the design and interpretation of clinical trials. The current investigation attempted to identify potential predictors of placebo response through examination of the placebo-controlled clinical trial database for escitalopram in 3 anxiety disorders and in major depressive disorder (MDD).
Method: Raw data from placebo-controlled studies (conducted from 2002 through the end of 2004) of escitalopram in patients meeting DSM-IV criteria for MDD and anxiety disorders (generalized anxiety disorder [GAD], social anxiety disorder [SAD], panic disorder) were used. Potential predictors examined were type of disorder, location of study, dosing regimen, number of treatment arms, gender of patients, and duration and severity of disorder.
Results: Placebo response (defined as the percent decrease from baseline in the reference scale) was higher in GAD and MDD studies conducted in Europe (p < .0001 and p = .0006, respectively) and was not associated with gender or duration of episode. In GAD, the placebo response rate was higher in a European fixed-dose study, which also had more treatment arms. In SAD and in U.S. specialist-treated MDD, a higher placebo response rate was predicted by decreased baseline disorder severity.
Conclusion: Additional work is needed before definitive recommendations can be made about whether standard exclusion criteria in clinical trials of antidepressants, such as mild severity of illness, maximize medication-to-placebo differences. This analysis in a range of anxiety disorders and MDD suggests that there may be instances in which the predictors of placebo response rate themselves vary across different conditions.
obsessive-compulsive disorder, double-blind, antidepressant, gad, disorders, escitalopram, panic disorder, severity, physicians, generalized anxiety disorder, major depression, social anxiety disorder, clinical-trials, dsm-iv, generalized anxiety, trials comparing placebo, major depressive disorder, placebo, predictors, continuation treatment, placebo-controlled study, drug response, clinical-trial, term treatment, social phobia
1741-1746
Stein, Dan J.
07cf0cbd-837d-49ac-aceb-1c393a2f3e00
Baldwin, David S.
1beaa192-0ef1-4914-897a-3a49fc2ed15e
Dolberg, Ornah T.
a39524fa-c5b6-40da-a674-d9fb280ebe2d
Despiegel, Nicolas
f941f6c7-ed0d-4bd2-83d5-b7ce7ff00cef
Bandelow, Borwin
2fbbae21-629e-4d76-b5d0-7dff1282d64d
Stein, Dan J.
07cf0cbd-837d-49ac-aceb-1c393a2f3e00
Baldwin, David S.
1beaa192-0ef1-4914-897a-3a49fc2ed15e
Dolberg, Ornah T.
a39524fa-c5b6-40da-a674-d9fb280ebe2d
Despiegel, Nicolas
f941f6c7-ed0d-4bd2-83d5-b7ce7ff00cef
Bandelow, Borwin
2fbbae21-629e-4d76-b5d0-7dff1282d64d

Stein, Dan J., Baldwin, David S., Dolberg, Ornah T., Despiegel, Nicolas and Bandelow, Borwin (2006) Which factors predict placebo response in anxiety disorders and major depression? An analysis of placebo-controlled studies of escitalopram. The Journal of Clinical Psychiatry, 67 (11), 1741-1746.

Record type: Article

Abstract

Background: The placebo response rate has increased in several psychiatric disorders and is a major issue in the design and interpretation of clinical trials. The current investigation attempted to identify potential predictors of placebo response through examination of the placebo-controlled clinical trial database for escitalopram in 3 anxiety disorders and in major depressive disorder (MDD).
Method: Raw data from placebo-controlled studies (conducted from 2002 through the end of 2004) of escitalopram in patients meeting DSM-IV criteria for MDD and anxiety disorders (generalized anxiety disorder [GAD], social anxiety disorder [SAD], panic disorder) were used. Potential predictors examined were type of disorder, location of study, dosing regimen, number of treatment arms, gender of patients, and duration and severity of disorder.
Results: Placebo response (defined as the percent decrease from baseline in the reference scale) was higher in GAD and MDD studies conducted in Europe (p < .0001 and p = .0006, respectively) and was not associated with gender or duration of episode. In GAD, the placebo response rate was higher in a European fixed-dose study, which also had more treatment arms. In SAD and in U.S. specialist-treated MDD, a higher placebo response rate was predicted by decreased baseline disorder severity.
Conclusion: Additional work is needed before definitive recommendations can be made about whether standard exclusion criteria in clinical trials of antidepressants, such as mild severity of illness, maximize medication-to-placebo differences. This analysis in a range of anxiety disorders and MDD suggests that there may be instances in which the predictors of placebo response rate themselves vary across different conditions.

This record has no associated files available for download.

More information

Published date: 2006
Keywords: obsessive-compulsive disorder, double-blind, antidepressant, gad, disorders, escitalopram, panic disorder, severity, physicians, generalized anxiety disorder, major depression, social anxiety disorder, clinical-trials, dsm-iv, generalized anxiety, trials comparing placebo, major depressive disorder, placebo, predictors, continuation treatment, placebo-controlled study, drug response, clinical-trial, term treatment, social phobia

Identifiers

Local EPrints ID: 62605
URI: http://eprints.soton.ac.uk/id/eprint/62605
PURE UUID: ebaca875-2e85-4e93-823b-6123e23196a8
ORCID for David S. Baldwin: ORCID iD orcid.org/0000-0003-3343-0907

Catalogue record

Date deposited: 05 Sep 2008
Last modified: 09 Jan 2022 02:48

Export record

Contributors

Author: Dan J. Stein
Author: Ornah T. Dolberg
Author: Nicolas Despiegel
Author: Borwin Bandelow

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×